
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen Inc. is positioned favorably in the biotechnology sector due to its advanced Enhanced Delivery Oligonucleotide platform, which has shown promising preclinical results in delivering oligonucleotides effectively across various tissues. With a current stock price of approximately $4 per share, the company's potential for significant upside is highlighted by best-case scenario projections indicating possible increases of 40% to 100% if clinical data demonstrates strong efficacy and safety. Additionally, PepGen's reported 53.7% splicing correction sets a high benchmark compared to competitors, reinforcing the credibility of its therapeutic advancements and suggesting that investor interest could grow as multi-dose data is released.
Bears say
PepGen Inc. is facing significant challenges that contribute to a negative outlook on its stock. Key risks include potential unexpected safety issues related to its Enhanced Delivery Oligonucleotide platform, the efficacy of PGN-EDODM1 being lower than anticipated based on earlier clinical data, and uncertainties surrounding the regulatory approval pathways for its products. Furthermore, the company's reliance on successful market execution and its ability to secure funding raises concerns about the feasibility of its development plans and meeting projected commercial revenue, which could adversely impact investor confidence and share performance.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares